Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

The financial performance, as indicated by the income statement, reveals a complex pattern of fluctuations over the observed period. Revenues demonstrate significant variability, with notable peaks and subsequent declines. Cost of revenues generally follows revenue trends, while operating and net income exhibit corresponding volatility. A detailed examination of specific revenue components and expense categories provides further insight.

Revenue Trends

Total revenues experienced a substantial increase from March 2021 to June 2021, followed by a decline. This pattern of increase and decrease continued throughout 2021 and 2022, though with less dramatic swings. Revenues remained relatively stable between March 2022 and December 2022. A decline is observed in the first quarter of 2023, followed by a recovery and then another decline through the first three quarters of 2024. The final quarter of 2024 shows a recovery, but this is followed by a decline in the first two quarters of 2025. Net product sales consistently represent the largest portion of revenue, while collaboration revenue contributes a significant and fluctuating amount. Other revenue remains a smaller, but growing, component.

Gross Profit Analysis

Gross profit mirrors the revenue trends, peaking in June 2021 and experiencing subsequent fluctuations. The gross profit margin, while not explicitly calculated, appears to be relatively consistent, suggesting that changes in gross profit are primarily driven by revenue volume rather than significant shifts in the cost of goods sold as a percentage of revenue. A slight decrease in gross profit is observed in the final quarters of the observed period.

Operating Expenses

Research and development (R&D) expenses remain consistently high throughout the period, with a general upward trend, particularly noticeable in the later quarters. Selling, general, and administrative (SG&A) expenses also exhibit a consistent level of expenditure, with some quarterly variations. The combined effect of these operating expenses significantly impacts income from operations. Acquired in-process R&D shows sporadic, large expenses in certain quarters.

Profitability

Income from operations demonstrates similar volatility to revenues and gross profit. Other income (expense), net, introduces additional fluctuations, with significant positive contributions in several quarters. Income before income taxes follows the pattern of operational income, influenced by other income and expenses. Net income exhibits substantial quarterly variations, mirroring the trends in income before taxes and being affected by income tax expense. The income tax rate appears to fluctuate, impacting the final net income figures.

Cost of Revenue Components

Both cost of goods sold and cost of collaboration and contract manufacturing contribute to the overall cost of revenues. Cost of goods sold generally represents the larger portion of these costs. Both components fluctuate with revenue levels, but cost of collaboration and contract manufacturing shows more pronounced variability. The combined impact of these costs is a significant factor in determining gross profit.

In summary, the financial performance is characterized by substantial revenue and income volatility. While R&D and SG&A expenses remain relatively stable, fluctuations in revenue, collaboration revenue, and other income significantly impact profitability. The observed trends suggest a business sensitive to external factors and potentially reliant on specific product launches or partnership agreements.